Contribute Try STAT+ Today

Top of the morning to you, and a fine one it is. Despite the perennial gloom lingering about, we are enjoying a shiny sun and blue skies that are greeting us on the Pharmalot campus. Small things still count, you know? This is another way of saying the proverbial cup of stimulation is always half full. Speaking of which, time to brew another. Our choice today is maple bourbon. Meanwhile, there is work to be done. So here are a few items of interest. We hope your day is peaceful and productive. And of course, stay safe — wear a mask. …

Johnson & Johnson (JNJ) published updated early data on its Covid-19 vaccine that show it provided participants in a clinical trial with at least some immunity after one dose, STAT explains. But the data offer only hints to a tantalizing question: Could the vaccine, given as a single shot, perform as well as the vaccines that U.S. regulators have already authorized, which are given as two? The data indicate the vaccine could produce immunity, but there was a big benefit to giving the participants a booster dose.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.